Article, Featured at SITC 2022, Demonstrates the Potential of Innovative Anti-CTLA-4 Antibody Delivery
This award further highlights the potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent, currently in Phase I/IIa
Strasbourg, France, November 14, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops cancer immunotherapies based on viral vectors, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotechnology company dedicated to the discovery and development of innovative immunomodulatory antibodies against cancer, announces that it has won the 2022 Best Paper Award from the Journal for ImmunoTherapy of Cancer (JITC) scientific journal in the Oncolytic Immunotherapy and local for an article describing the work carried out by researchers from both companies on BT-001. This award was given on the occasion of the annual conference of the Society for Immunotherapy of Cancer (SITC) which was held from November 8 to 12, 2022 in Boston (USA).